All Trials

IGNITE: A Phase 2 Study of Maintenance Combinatorial Myeloid Immunotherapy in Patients With Unresectable Pancreatic Ductal Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable PDAC (metastatic or locally advanced) who have completed 16–24 weeks of first-line chemotherapy with no progression (stable disease or partial response), ECOG 0–1, measurable disease, and willingness for paired tumor biopsies. Patients receive maintenance IV odetiglucan (soluble β-glucan innate/myeloid immune activator engaging complement/CR3 pathways) plus IV mitazalimab (agonistic anti-CD40 antibody to activate APCs and promote T-cell priming/macrophage reprogramming), with primary efficacy focused on metastatic patients with partial response after induction chemotherapy.

ClinicalTrials.gov ID: NCT07199764

A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: For adults with unresectable recurrent/metastatic HNSCC (oral cavity/oropharynx/hypopharynx/larynx) with measurable disease and ECOG 0–2 who have radiographic progression on/after prior immune checkpoint inhibitor therapy and no prior EGFR-targeted therapy or taxane for R/M disease. Treatment is oral NRC-2694-A (investigational EGFR tyrosine kinase inhibitor) 300 mg daily plus paclitaxel 175 mg/m² IV every 21 days (≥6 cycles per protocol).

ClinicalTrials.gov ID: NCT05283226

A Phase 3, Multicenter, Randomized, Open-label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients With Previously Treated Advanced Biliary Tract Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or locally advanced/unresectable biliary tract cancer (intrahepatic/extrahepatic cholangiocarcinoma or gallbladder cancer) and ECOG 0–1 whose disease has progressed after exactly one prior platinum-based systemic regimen for advanced disease (prior matched targeted therapy for actionable alterations and/or PD-1/PD-L1 for MSI-H allowed). Patients are randomized to nanvuranlat, an IV small-molecule LAT1 (SLC7A5) amino acid transporter inhibitor intended to disrupt essential amino acid uptake and downstream mTOR signaling, versus physician’s choice of FOLFOX, FOLFIRI, or best supportive care (with initial dose-regimen selection followed by confirmatory comparison).

ClinicalTrials.gov ID: NCT07265674

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated stage IV metastatic squamous NSCLC (ECOG 0–1; measurable disease; requires non-irradiated metastatic tumor tissue for sequencing; controlled HIV and treated/undetectable HBV/HCV allowed) receive first-line pembrolizumab plus carboplatin and a taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab maintenance. Participants are randomized double-blind to add V940 (mRNA-4157/intismeran autogene), an individualized lipid nanoparticle mRNA neoantigen vaccine encoding up to 34 patient-specific neoantigens to stimulate CD4+/CD8+ T-cell responses, versus placebo.

ClinicalTrials.gov ID: NCT07221474

An Open-Label, Multicenter, Phase 2 Study With Safety Lead-In of Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab in Patients With Angiosarcoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with locally advanced/unresectable or metastatic, RECIST-measurable cutaneous angiosarcoma with at least one injectable lesion and ECOG 0–1 who have progressed on prior taxane/anthracycline chemotherapy and on an immunotherapy-based regimen within 6 months. Patients receive intratumoral vusolimogene oderparepvec (RP1), an HSV-1–derived oncolytic immunotherapy engineered to express GM-CSF and a fusogenic glycoprotein to enhance immunogenic tumor cell death/antigen presentation, in combination with pembrolizumab (PD-1 blockade).

ClinicalTrials.gov ID: NCT06898970

A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults (≥18) with unresectable locally advanced or metastatic alveolar soft part sarcoma (currently enrolling; prior systemic therapy allowed except prior cediranib) receive oral anlotinib (AL3818/catequentinib), a multitarget anti-angiogenic TKI (VEGFR1–3/FGFR1–4/PDGFRα/β/c-Kit), 12 mg daily on a 14-days-on/7-days-off schedule until progression/toxicity. Closed cohorts previously randomized patients with progressed leiomyosarcoma or synovial sarcoma to anlotinib versus dacarbazine (with crossover to anlotinib at progression) or anlotinib versus placebo in leiomyosarcoma.

ClinicalTrials.gov ID: NCT03016819

A Feasibility Study of Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma and Merkel Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/recurrent/metastatic cutaneous squamous cell carcinoma or Merkel cell carcinoma (mixed histology allowed) that has progressed after prior anti–PD-1/PD-L1 therapy (or recurred within 6 months of perioperative ICI) and who have a resectable lesion for TIL harvest. Patients receive tumor harvest for autologous ex vivo expanded TIL therapy lifileucel (LN-145; reinfusion of tumor-reactive T cells) after cyclophosphamide/fludarabine lymphodepletion, followed by high-dose IL-2 (aldesleukin) support.

ClinicalTrials.gov ID: NCT07288073

Neoadjuvant REGN2810 (Cemiplimab) or REGN2810 (Cemiplimab) Plus REGN3767 (Fianlimab) in Cutaneous Basal Cell Carcinoma of the Head and Neck

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with locally advanced cutaneous basal cell carcinoma of the head and neck where standard surgery would be unresectable or highly morbid receive neoadjuvant cemiplimab, an anti–PD-1 antibody, before planned surgery. A second cohort receives cemiplimab plus fianlimab, an anti–LAG-3 antibody, to assess whether dual checkpoint blockade improves tumor response and enables organ-preserving surgery.

ClinicalTrials.gov ID: NCT05929664

A Phase 2 Study to Investigate Ubamatamab With and Without REGN7075 in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls ECOG 0–1 adults with measurable stage IIIB/IIIC/IV NSCLC previously treated with standard therapy including platinum chemotherapy, with tumor tissue available for MUC16 testing. Patients receive ubamatamab, an IV MUC16×CD3 T-cell–redirecting bispecific antibody, with sarilumab for CRS mitigation, with or without REGN7075, an EGFR×CD28 costimulatory bispecific antibody.

ClinicalTrials.gov ID: NCT07154290

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling fit adults (ECOG 0–1) with previously untreated KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma. Patients are randomized to first-line mFOLFIRINOX or NALIRIFOX plus setidegrasib/ASP3082, an IV KRAS G12D-targeted protein degrader, versus placebo plus the same chemotherapy backbone.

ClinicalTrials.gov ID: NCT07409272